I'd presume Roche will now spend 9-12mths on pre-clinical trials.
In the case of an active drug lead, in-vitro(test tube) and in-vivo(animal testing) are conducted. If results satisfy Roche, milestone payments would flow and clinical trials(human) will then go ahead.
I'm not sure what trials would be carried out if the peptide is a passive carrier.
Whether PYCs peptide is an active drug lead or a carrier for an active molecule, toxicology tests would show any adverse effects.
Hard to know what has already been done. Would be nice to get more detail.
Numerator: you're more knowledgeable, can you add to this? ST
PYC Price at posting:
6.3¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)